Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22369027 | 0.83 | MAOB (0.44) | MAOBCYSLTR1NFE2L2 | |
| SCHEMBL131026 | 0.80 | CYSLTR1 (0.43) | MAOBCYSLTR1 | |
| SCHEMBL22457039 | 0.80 | CYSLTR1 (0.44) | MAOBCYSLTR1 | |
| SCHEMBL20111180 | 0.77 | CYSLTR1 (0.42) | CYSLTR1 | |
| SCHEMBL25111145 | 0.77 | ITGB3 (0.51) | CYSLTR1 | |
| SCHEMBL23446721 | 0.76 | CYSLTR1 (0.51) | CYSLTR1 | |
| SCHEMBL20848284 | 0.74 | CYSLTR1 (0.39) | CYSLTR1 | |
| SCHEMBL20834271 | 0.73 | FFAR4 (0.49) | CYSLTR1 | |
| SCHEMBL20710459 | 0.73 | CYSLTR1 (0.39) | MAOBCYSLTR1 | |
| SCHEMBL22239229 | 0.72 | CYSLTR1 (0.50) | CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654846-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654846-B2 | Autotaxin inhibitory compounds | ENPP2, RNASE1, ATXN10 | MAOB 314/4885CYSLTR1 835/4885KEAP1 365/4885 |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | ENPP2, RNASE1, ATXN10 | MAOB 314/4885CYSLTR1 835/4885KEAP1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.